Delayed-type hypersensitivity and hepatitis B vaccine responses, in vivo markers of cellular and humoral immune function, and the risk of AIDS or death

• Published in: Vaccine 2014-06, Vol.32 (27), p.3341-3344
• Main Authors: Patterson, Shane B, Landrum, Michael L, Okulicz, Jason F
• Format: Article
• Language: English
• Subjects: Acquired immune deficiency syndrome; Acquired Immunodeficiency Syndrome - immunology; Acquired Immunodeficiency Syndrome - mortality; Adult; Age; AIDS; Allergy and Immunology; Anergy; Antibody Formation; Antigens; Antiretroviral drugs; Applied microbiology; Armed forces; Biological and medical sciences; Clonal Anergy; Confidence intervals; Delayed-type hypersensitivity; Disease; Disease Progression; Drug therapy; Ethnicity; Female; Fundamental and applied biological sciences. Psychology; Gender; Hepatitis; Hepatitis B Antibodies - blood; Hepatitis B vaccine; Hepatitis B Vaccines - administration & dosage; Hepatitis B virus; HIV; HIV Infections - immunology; HIV Infections - mortality; Human immunodeficiency virus; Human viral diseases; Humans; Hypersensitivity; Hypersensitivity, Delayed - immunology; Immune response; Immunity, Cellular; Infections; Infectious diseases; Male; Medical sciences; Microbiology; Mortality; Multivariate Analysis; Proportional Hazards Models; Prospective Studies; Public health; Retrospective Studies; Vaccines; Vaccines, antisera, therapeutical immunoglobulins and monoclonal antibodies (general aspects); Viral diseases; Viral diseases of the lymphoid tissue and the blood. Aids; Viral hepatitis
• ISSN: 0264-410X; 1873-2518
• DOI: 10.1016/j.vaccine.2014.04.049

Highlights • Responsiveness to HBV vaccine and DTH testing can predict HIV disease progression. • We evaluated HBV vaccine seroresponses in those with non-anergic DTH results. • HBV vaccine response predicted AIDS or death even in non-anergic persons with HIV.